EGFR and non-small cell lung carcinoma: Similarly, the RADIANT phase III trial, comparing 2-year erlotinib (a first-generation EGFR TKI) vs. placebo in an NSCLC adjuvant setting with EGFR-expressing tumors, but not necessarily EGFR-mutated tumors, demonstrated no benefit in terms of DFS (HR = 0.90, 95% CI 0.74–1.10, p = 0.32) or OS (HR = 1.13, 95% CI 0.88–1.44, p = 0.33) [43].